SCP Hip Outcomes Study
A Longitudinal Outcomes Study of the Subchondroplasty® Procedure in the Hip
Sponsor: Zimmer Biomet
Listed as NCT03494660, this observational or N/A phase trial focuses on Avascular Necrosis of Hip and Bone Marrow Edema and remains completed. Sponsored by Zimmer Biomet, it has been updated 19 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)This study is designed as a post-market, single arm, non-randomized multi-center investigation. Male and female subjects, at least 18 years of age, with at least one subchondral bone defect in the form of a cyst and/or bone marrow lesion (BML), insufficiency fracture or bone defect associated with early stage avascular osteonecrosis (AVN) in the femoral head, femoral neck and/or acetabulum who are suitable candidates for use of AccuFill during the Subchondroplasty Procedure are eligible for enrollment in this study. A maximum of 15 study sites, in the United States of America, will enroll a target of 50 subjects. Each Investigator must obtain IRB approval, or favorable opinion by an EC, prior to consent of the first subject; no study-related procedures can occur without the approval and oversight of a registered IRB or EC. If the study site does not have an IRB of record, a central IRB may be utilized upon approval by Zimmer Biomet. Demographics, medical history, hip history and use of pain medication and therapy will be recorded at the time of subject consent. Additionally, patient reported outcomes measures will be obtained pre-operatively. Operative details including the SCP Procedure, concomitant surgical procedures and intraoperative safety events will be...
This study is designed as a post-market, single arm, non-randomized multi-center investigation.
Male and female subjects, at least 18 years of age, with at least one subchondral bone defect in the form of a cyst and/or bone marrow lesion (BML), insufficiency fracture or bone defect associated with early stage avascular osteonecrosis (AVN) in the femoral head, femoral neck and/or acetabulum who are suitable candidates for use of AccuFill during the Subchondroplasty Procedure are eligible for enrollment in this study.
A maximum of 15 study sites, in the United States of America, will enroll a target of 50 subjects.
Each Investigator must obtain IRB approval, or favorable opinion by an EC, prior to consent of the first subject; no study-related procedures can occur without the approval and oversight of a registered IRB or EC. If the study site does not have an IRB of record, a central IRB may be utilized upon approval by Zimmer Biomet.
Demographics, medical history, hip history and use of pain medication and therapy will be recorded at the time of subject consent. Additionally, patient reported outcomes measures will be obtained pre-operatively. Operative details including the SCP Procedure, concomitant surgical procedures and intraoperative safety events will be recorded at the time of surgery. Prospective subjects will be considered enrolled in this study once their Subchondroplasty Procedure has been performed.
Subjects will complete only the Numeric Pain Scale at 2 weeks post-operatively. Thereafter, subjects will complete self-reported outcomes measures post-operatively at 6 weeks, 12 weeks, 6 months, 1 year and 2 years. These measures include information on pain medication and therapy, pain levels, function, activity and subject satisfaction. Screening for adverse events and conversion will occur throughout the study.
Subjects will complete the study at 2 years or will be withdrawn if they undergo conversion of the Subchondroplasty site. For the purposes of this protocol, a conversion will be defined as total hip arthroplasty or any procedure involving removal of the AccuFill material on the index hip.
Status Flow
Change History
19 versions recorded-
Apr 21, 2026 — Present [daily]
Completed
Status: Active Not Recruiting → Completed
-
Oct 2024 — Apr 2026 [monthly]
Active Not Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting
▶ Show 14 earlier versions
-
Sep 2023 — Jun 2024 [monthly]
Active Not Recruiting
-
Nov 2022 — Sep 2023 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Nov 2021 — Nov 2022 [monthly]
Recruiting
-
May 2021 — Nov 2021 [monthly]
Recruiting
-
Jan 2021 — May 2021 [monthly]
Recruiting
-
Apr 2020 — Jan 2021 [monthly]
Recruiting
-
Feb 2020 — Apr 2020 [monthly]
Recruiting
-
Dec 2019 — Feb 2020 [monthly]
Recruiting
-
Jul 2019 — Dec 2019 [monthly]
Recruiting
-
Dec 2018 — Jul 2019 [monthly]
Recruiting
-
Sep 2018 — Dec 2018 [monthly]
Recruiting
-
Aug 2018 — Sep 2018 [monthly]
Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
Post-market clinical outcomes study to collect data on the short- and long-term outcomes for subjects who are undergoing or have undergone the Subchondroplasty® (SCP®) Procedure in the hip in a standard clinical setting. Outcomes to be assessed include medication usage, pain, function, activity levels and patient satisfaction.
Contact Information
- Zimmer Biomet
For direct contact, visit the study record on ClinicalTrials.gov .